Advertisement
2024 International Myeloma Society Annual Meeting
Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed With Multiple Myeloma
In the phase III CEPHEUS trial,1 the achievement of undetectable measurable residual disease (or MRD negativity)—the primary endpoint—was met by 61% of patients with transplant-ineligible or deferred...
Evolving Role of MRD Status in Multiple Myeloma
The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of th...
Advertisement
Advertisement
Dec
Today In Oncology09
Advertisement
© 2024 HSP News Service, L.L.C.
